Summit Therapeutics Inc. Increase (Decrease) in Other Operating Assets
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Other Operating Assets of $4.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-02-23
- Summit Therapeutics Inc. increase (decrease) in other operating assets for the quarter ending 2024-12-31 was -$365.00K, a 948.84% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for the quarter ending 2024-09-30 was $151.00K, a 93.85% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for the quarter ending 2024-06-30 was $275.00K, a 80.78% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for the quarter ending 2024-03-31 was -$2.53M.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for fiscal 2025 was $4.88M.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for fiscal 2024 was -$2.47M, a 172.20% decline from fiscal 2023.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for fiscal 2023 was $3.42M.
- Summit Therapeutics Inc. increase (decrease) in other operating assets for fiscal 2022 was -$215.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.88M 10-K · filed 2026-02-23 | |||
| 2024-12-31 | -$365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$214.00K derived: sum of 2 quarters · filed 2026-02-23 | $61.00K derived: sum of 3 quarters · filed 2026-02-23 | -$2.47M 10-K · filed 2026-02-23 |
| 2024-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $426.00K derived: sum of 2 quarters · filed 2024-10-30 | -$2.10M 10-Q · filed 2024-10-30 | -$2.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.26M 10-Q · filed 2024-08-06 | -$2.21M derived: sum of 3 quarters · filed 2026-02-23 | $242.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$2.53M 10-Q · filed 2024-05-01 | -$2.49M derived: sum of 2 quarters · filed 2026-02-23 | -$33.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.40M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.50M derived: sum of 2 quarters · filed 2026-02-23 | $3.93M derived: sum of 3 quarters · filed 2026-02-23 | $3.42M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $3.89M derived: sum of 2 quarters · filed 2024-10-30 | $3.38M 10-Q · filed 2024-10-30 | $3.72M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $923.00K 10-Q · filed 2024-08-06 | $1.27M derived: sum of 3 quarters · filed 2025-02-24 | -$702.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | -$508.00K 10-Q · filed 2024-05-01 | -$165.00K derived: sum of 2 quarters · filed 2025-02-24 | -$2.13M derived: sum of 3 quarters · filed 2025-02-24 | -$1.09M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$1.63M derived: sum of 2 quarters · filed 2025-02-24 | -$585.00K derived: sum of 3 quarters · filed 2025-02-24 | -$215.00K 10-K · filed 2025-02-24 |
| 2022-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$928.00K derived: sum of 2 quarters · filed 2023-11-07 | -$558.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.41M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $370.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$104.00K 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $24.00K 10-K/A · filed 2022-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |